Janssen has filed a new formulation of its Darzalex in the US for the rare and potentially fatal disease light chain (AL) amyloidosis.

Johnson & Johnson’s pharmaceuticals unit said it had filed Darzalex Faspro (daratumumab+hyaluronidase), a subcutaneous formulation of the drug already approved in several blood cancers. Click here to read more.